Literature DB >> 12409816

Physical activity, health impairments, and disability in neuromuscular disease.

Craig M McDonald1.   

Abstract

Reduced physical activity is a consequence of progressive neuromuscular diseases, which negatively impacts quality of life and health outcomes. Reduced functional muscle mass is common to all neuromuscular diseases and results from both atrophy of disuse secondary to a sedentary lifestyle and muscle degeneration secondary to the disease itself. This review summarizes current concepts relating to the impact of reduced physical activity on health and fitness, potential determinants of physical activity levels in neuromuscular diseases, and new approaches to the quantitative measurement of physical activity in neuromuscular disease populations. The interrelationship of disease pathophysiology, impairment, functional limitation, disability, and societal limitation in the determination of physical activity in the community in neuromuscular diseases is discussed using Duchenne muscular dystrophy as an example. Future research pertaining to physical activity in neuromuscular disease will need to focus on the development of scientifically based recommendations concerning optimal exercise approaches with both disease-specific and general guidelines.

Entities:  

Mesh:

Year:  2002        PMID: 12409816     DOI: 10.1097/00002060-200211001-00012

Source DB:  PubMed          Journal:  Am J Phys Med Rehabil        ISSN: 0894-9115            Impact factor:   2.159


  42 in total

1.  Perspectives on Active Video Gaming as a New Frontier in Accessible Physical Activity for Youth With Physical Disabilities.

Authors:  Jennifer L Rowland; Laurie A Malone; Cali M Fidopiastis; Sangeetha Padalabalanarayanan; Mohanraj Thirumalai; James H Rimmer
Journal:  Phys Ther       Date:  2015-08-27

2.  Electromyographic activity and kinematics of sit-to-stand in individuals with muscle disease.

Authors:  Gülşah Sütçü; Ali İmran Yalçın; Ender Ayvat; Özge Onursal Kılınç; Fatma Ayvat; Mert Doğan; Gülcan Harput; Sibel Aksu Yıldırım; Muhammed Kılınç
Journal:  Neurol Sci       Date:  2019-06-19       Impact factor: 3.307

Review 3.  Physical inactivity and cognitive functioning: results from bed rest studies.

Authors:  Darren M Lipnicki; Hanns-Christian Gunga
Journal:  Eur J Appl Physiol       Date:  2008-09-17       Impact factor: 3.078

Review 4.  The role of the neuromuscular medicine and physiatry specialists in the multidisciplinary management of neuromuscular disease.

Authors:  Craig M McDonald; William M Fowler
Journal:  Phys Med Rehabil Clin N Am       Date:  2012-08       Impact factor: 1.784

Review 5.  Strength training and aerobic exercise training for muscle disease.

Authors:  Nicoline Bm Voet; Elly L van der Kooi; Baziel Gm van Engelen; Alexander Ch Geurts
Journal:  Cochrane Database Syst Rev       Date:  2019-12-06

6.  A Randomized Crossover Trial of Dalfampridine Extended Release for Effect on Ambulatory Activity in People with Multiple Sclerosis.

Authors:  Theodore R Brown; Virginia I Simnad
Journal:  Int J MS Care       Date:  2016 Jul-Aug

7.  Peak Jump Power Reflects the Degree of Ambulatory Ability in Patients with Mitochondrial and Other Rare Diseases.

Authors:  Christopher Newell; Barbara Ramage; Alberto Nettel-Aguirre; Ion Robu; Aneal Khan
Journal:  JIMD Rep       Date:  2016-09-13

8.  Physical training in boys with Duchenne Muscular Dystrophy: the protocol of the No Use is Disuse study.

Authors:  Merel Jansen; Imelda Jm de Groot; Nens van Alfen; Alexander Ch Geurts
Journal:  BMC Pediatr       Date:  2010-08-06       Impact factor: 2.125

9.  Community walking activity in neurological disorders with leg weakness.

Authors:  M E Busse; C M Wiles; R W M van Deursen
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-03       Impact factor: 10.154

10.  Effects of training and albuterol on pain and fatigue in facioscapulohumeral muscular dystrophy.

Authors:  E L van der Kooi; J S Kalkman; E Lindeman; J C M Hendriks; B G M van Engelen; G Bleijenberg; G W Padberg
Journal:  J Neurol       Date:  2007-03-14       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.